Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Assess the Steady-State Bioequivalence of Once-Weekly Corplex™ 10mg Donepezil Transdermal Delivery System Compared to Daily Oral Administration of Aricept

Trial Profile

A Study to Assess the Steady-State Bioequivalence of Once-Weekly Corplex™ 10mg Donepezil Transdermal Delivery System Compared to Daily Oral Administration of Aricept

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Donepezil (Primary) ; Donepezil
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics; Registrational
  • Sponsors Corium International
  • Most Recent Events

    • 31 Jul 2018 Status changed to completed.
    • 14 May 2018 According to a Corium International media release, based on this study, the company is planning to a submission of a Section 505(b)(2) New Drug Application (NDA) in the first quarter of 2019.
    • 24 Apr 2018 Planned End Date changed from 1 Aug 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top